Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation

Am J Hematol. 2021 Jul 1;96(7):E237-E239. doi: 10.1002/ajh.26179. Epub 2021 May 5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis*
  • Leukemia, Myeloid, Acute / etiology
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / therapy*
  • Middle Aged
  • Mutation
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / etiology
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm, Residual
  • Risk Factors
  • Transplantation, Homologous
  • Young Adult